As Research!America prepares for our 24th Advocacy Awards Dinner , we want readers to learn more about our award recipients. We are continuing our Tuesday series leading up to the March 11 event. Please meet Dr. Paul Offit, co-recipient of the Geoffrey Beene Foundation Builders of Science Award. Paul A.Offit MD Professor of Pediatrics, Children's' Hospital of Philadelphia When did you know you were an advocate for scientific research and innovation? I chose to go into pediatrics because of my love of children. The reason for that passion was that I was in a polio ward when I was five years old in the mid-1950s. It was at a time when there was only one visiting hour a week with maybe a...

Dear Research Advocate, There’s a lot going on right now, so this letter is a bit longer than usual. Stay with me! Let’s start with the Super Bowl. According to the National Retail Federation, this year’s Super Bowl-related spending is on track to be the highest ever: $17.2 billion. That’s enough to fund: NIH-sponsored research on chronic pain for more than 26 years. CDC’s National Center for Injury and Prevention Control for almost 27 years. The entire Agency for Healthcare Research and Quality budget , which plays a profoundly underappreciated role in driving better health and healthcare, for more than 38 years. This is a wealthy country; we don’t need to stop spending on all things Super...

Dear Research Advocate, This week’s headlines about the coronavirus certainly underscore how nimble and prepared our federal research agencies must always be. It’s a compelling reason health research agencies must be well-funded and well-coordinated. The CDC, FDA, and NIH trifecta are on high alert, playing leading roles in global efforts to identify and contain the deadly virus. After Chinese researchers sequenced the virus’ genome, they posted it in GenBank, a database managed by NIH. The CDC has submitted a diagnostic test to the FDA for use in select public health labs around the country. NIH is working with industry on a vaccine they hope to have ready for human trials in a few months...

Dear Research Advocate, Last summer, the administration announced a new policy targeting fetal tissue research. The Washington Post reported this week on the troubling consequences for scientists, scientific progress, and thus patients. Research!America stood with patients and researchers against this retrograde policy change when it was first contemplated and, as part of a coalition led by the International Society for Stem Cell Research (ISCCR), we continue to push back. (It’s well to remember that fetal tissue research is not only playing a significant role today in research for vaccine development, Down syndrome, MS, and Parkinson’s, but its untapped potential holds significance for...